CY with CYLTEZO

Boehringer Ingelheim (BI) was preparing for the commercial launch of it's interchangeable biologic CYLTEZO in late 2023 and was indicated for patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis​, and 6 additional indications. Many starting CYLTEZO may have used HUMIRA, while others are new to biologics. 

To enhance BI and CYLTEZO familiarity, we developed a robust patient experience, including a comprehensive website, eCRM program, injection training videos, Nurse Educator materials, and more, ensuring patients feel confident starting and staying on CYLTEZO.